Growth, clinical and neurodevelopmental outcomes at school age are similar for children who received 1-year lamivudine or lopinavir/ritonavir HIV prophylaxis in early life

Growth, clinical and neurodevelopmental outcomes at school age are similar for children who received 1-year lamivudine or lopinavir/ritonavir HIV prophylaxis in early life

Abstract In the ANRS 12174 trial, HIV-exposed uninfected African neonates who received lopinavir-ritonavir (LPV/r) prophylaxis for 1 year exhibited slower growth from birth to week 50 compared with those receiving lamivudine (3TC). We assessed whether this difference in growth persisted over time, a...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Nicolas Nagot, Mandisa Singata-Madliki, Amandine Cournil, Joyce Nalugya, Souleymane Tassembedo, Catherine Quillet, Melany W. Tonga, James Tumwine, Nicolas Meda, Chipepo Kankasa, Mwiya Mwiya, Paul Bangirana, Marianne Peries, Joanne Batting, Ingunn M. S. Engebretsen, Thorkild Tylleskär, Philippe Vande Perre, Grace Ndeezi, Jean-Pierre Molès
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/3c2f1f5d320041d796767d8a985af567
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/3c2f1f5d320041d796767d8a985af567

Ejemplares similares